Endocrine Abstracts

Despite that the standard treatment for hypothyroidism is Levothyroxine, it is now recognised that a certain group of patients would benefit from treatment with Liothyronine either alone or in combination with Levothyroxine. Compared to Levothyroxine, Liothyronine has shorter-half life and can be associated with less predictable biochemical outcomes. In 2021, we published the outcome of the 1 ^st cycle of audit of use of Liothyronine at the University Hospital of Leicester (UHL) NHS Trust. Accordingly, we implemented changes to our practice. In this 2 ^nd cycle, we reassessed our prescribing practice against the regional and national guidelines and compared the outcomes of both cycles to produce further recommendations.

Methods: Retrospective database search of patients who were taking Liothyronine between September 2022-September 2023. We combined endocrine electronic database search with manual list of patients who picked up Liothyronine from UHL pharmacy.

Results: see Table (1)

Discussion & Conclusion: Compared to the previous cycle in 2021;

• There has been a slight improvement in achieving biochemical control in the 2 ^nd cycle compared to the 1 ^st (normal TSH in 31.7% vs 23.8%).

• There has been an improved practice in screening for complications including DEXA (40% vs 14%) and ECG (18.3% vs. 0%) and documenting QOL questionnaire (51.7% vs. 10%).Despite the above, we should still aim to achieve 100% target in screening for complications and assessment of QOL.